Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Eukaryotic Gene Expression
Factor de Impacto: 1.841 Factor de Impacto de 5 años: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimir: 1045-4403
ISSN En Línea: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2017019418
pages 237-246

TSG101: Tumor Susceptibility Gene 101 (tsg101) Product−Role in Therapy Against HIV/AIDS

Muhammad Imran Qadir
Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Bosan Road, Multan, Pakistan
Maria Zafar
Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan

SINOPSIS

HIV infection presents a major community health hazard, partially because the HIV virus is capable of evading antiretroviral therapies. Most anti-HIV drugs were intended to target virus-encoded mechanisms; however, some host-encoded molecules comparatively execute a vital role in the life cycle of virus. Thus, these might be considered as target sites for antiviral agents. TSG101 is important among these antiviral therapies because, as a cytoplasmic molecule, it facilitates viral budding and release. In this review, HIV-infected cells have TSG101 on their surface and thus can be used in antibody-based therapies. The development of a monoclonal antibody CB8-2 lessens the assembly of viruses from infected cells. This mechanism represents the potential use of TSG101-directed antibodies to fight against AIDS.


Articles with similar content:

A CCL2-Based Fusokine as a Novel Biopharmaceutical for the Treatment of CCR2-Driven Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.30, 2010, issue 5
Jacques Galipeau, Moutih Rafei
Role of p53 in Systemic Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.34, 2014, issue 6
Hirotoshi Kawashima, Hiroshi Nakajima, Hiroaki Takatori, Kotaro Suzuki
The TRAIL: TRAILshort Axis in HIV Immunopathology
Critical Reviews™ in Immunology, Vol.38, 2018, issue 6
Andrew D. Badley, Geeta Paranjape, Fatma Aboulnasr
Role of Galectin-3 in the Initial Control of Leishmania Infection
Critical Reviews™ in Immunology, Vol.34, 2014, issue 2
Guillaume St-Pierre, Pampa Bhaumik, Isabelle Pelletier, Sachiko Sato
Immunologic Nonresponsiveness to Tumors
Critical Reviews™ in Oncogenesis, Vol.9, 1998, issue 1
Martine Extermann, Scott J. Antonia, Richard A. Flavell